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In 1909, Abelous and Bardier described a blood-
pressure-lowering substance in human urine [1], a
finding that was confirmed by Frey in 1926 [2].
Kraut, Frey, and Werle believed the hypotensive
principle of urine was of pancreatic origin and
named it kallikrein—a word derived from the Greek
term for pancreas [3]. It is now known that kalli-
kreins occur in plasma and in several glandular
tissues, for example, kidney, pancreas, intestine,
and salivary and sweat glands [4]. Kallikreins are a
heterogeneous group of serine proteases that act on
plasma protein substrates, kininogens, to liberate
peptides termed kinins [4]. From kininogen, plasma
kallikreins release the nonapeptide bradykinin,
whereas glandular kallikreins release the decapep-
tide lysylbradykinin [4]. These peptides have a
broad spectrum of biological activities, ranging
from stimulation of sperm motility to inhibition of
postjunctional events at the renal vascular neuroef-
fector junction. The discovery by Terragno et al [5]
and McGiff et al [61 that bradykinin stimulates
release of prostaglandins is a milestone in kinin
research over the past decade, and led to the
proposal that the kallikrein-kinin and arachidonate-
prostaglandin systems are related. It now appears
that interactions of kinins and prostaglandins are a
feature of biological processes as diverse as those
involved in inflammation and in regulation of renal
function. In this paper, we analyze the evidence for
a relationship between the renal kallikrein-kinin and
prostaglandin (PG) systems, and discuss the signifi-
cance of such relationship with regard to renal
hemodynamic and excretory functions. Figure 1
depicts the proposed relationship.
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The kallikrein-kinin system: Determinants of intrarenal
activity
In 1966, Carvaiho and Diniz found in homoge-
nates of rat kidney a kinin-forming enzyme indistin-
guishable from urinary kallikrein [7]. Renal and
urinary kallikrein resemble each other, and both
differ markedly from plasma kallikrein in terms of
physical and biochemical properties, immunologic
characteristics, and profile of inhibition by several
natural proteinase inhibitors [4]. From rat kidney
slices that had been incubated with 3H-L-leucine,
Nustad, Vaaje, and Pierce [8] isolated four species
of radiolabeled kallikrein that were indistinguish-
able from corresponding species of the enzyme
found in urine; they concluded that cellular ele-
ments of the kidney elaborate kallikrein and then
release the enzyme into urine. Renal kallikrein is
associated primarily with the plasma membrane-
enriched fraction of renal cortical tissue [91, and its
activity decreases from the outer to the inner cortex
with little activity occurring in the medulla and
papilla of the kidney [101. In the rat kidney, kalli-
krein is localized in the apical region of cells of the
distal nephron [11, 121, at which site it is released
into the tubular fluid [14]. Release of the enzyme
into the renal vascular compartment [14, 15], and
interstitium [161 has also been suggested but is less
well substantiated. Recently, Chao and Margolius
[17] demonstrated that the active site of kallikrein
faces the external environment in dispersed cortical
cells, suggesting that renal kallikrein is an ectoen-
zyme.
Interaction of renal kallikrein with kininogen
within the kidney results in generation of lysyl-
bradykinin. This event may be regulated by one or
more kallikrein inhibitors found in the kidney and in
urine [18, 19]. Scicli et al concluded from stop-flow
studies in the dog that kinins are formed, and first
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Fig. 1. Relationship between renal kallikrein-kinin and prosta-
glandin systems. Kinins generated by kallikrein in the distal
nephron and probably in the renal interstitium stimulate produc-
tion of prostaglandins by the kidney.
appear in the tubular fluid, in the most distal
segments of the nephron [20]. Lysyl-bradykinin
entering the tubular compartment is in part convert-
ed to bradykinin by an aminopeptidase that re-
moves the N-terminal lysine from the decapeptide
[211, and large quantities of both peptides are found
in urine [22]. Methionyl-lysyl-bradykinin, a third
kinin found in urine, is generated by uropepsin in
urine acidified after voiding; as it does not occur in
fresh frozen urine, or in specimens containing an
inhibitor of pepsin, the undecapeptide is most likely
an artifact [231. That urinary kinins originate intra-
renally [241 in the distal nephron is well accepted,
but information on the source of kininogen, and on
the exact site(s) of kinin generation in the distal
nephron, is scarce. Kininogen occurs in plasma
[251, and in small amounts in urine [221, and possi-
bly, in the kidney. Two types have been described
in plasma, one having high molecular weight, the
other low; renal kallikrein liberates kinin from both
forms of kininogen but low-molecular-weight kinin-
ogen is the preferred substrate [25]. It is conceiv-
able, but as yet unproven, that low-molecular-
weight kininogen is filtered in the glomeruli, and
escapes tubular reabsorption in the proximal tu-
bules, reaching sites in the distal nephron where it is
acted on by urine kallikrein, or by kallikrein at the
renal distal tubular cell surface. It is less likely that
the interaction of kallikrein and its substrate occurs
in the renal interstitium, and that the kinin subse-
quently escapes into the tubular fluid.
Enzymes termed kininases are of major impor-
tance in determining the intrarenal level of kinins
[26]. Probably the most abundant renal kininase is a
peptidyl dipeptidase, kininase II, that inactivates
kinins by cleaving C-terminal Phe-Arg. This en-
zyme, which also converts angiotensin I to angio-
tensin II, is associated primarily, but not exclusive-
ly, with cells of the proximal tubule [9, 261. That
blockade of kininase II by specific inhibitors results
in a substantial increase in the urinary excretion
rate of kinins indicates that degradation of kinins by
kininases is of major significance in determining the
intrarenal level of kinins [24]. It follows, then, that
the intrarenal activity of the kallikrein-kinin system,
viz., the concentration of kinins at specific effector
sites, depends on the balance between kinin gener-
ating and degrading processes within the kidney. In
turn, these processes are regulated by many fac-
tors, including the availability of kininogen and the
concentrations of kallikrein, kininases, and their
respective inhibitors.
The renal arachidonate-prostaglandin system as
affected by kinins
In 1965, Lee et a! [27] reported isolation from
lapine renal medulla of a blood-pressure-lowering
material that later work [28] revealed was a mixture
of several prostanoids. Synthesis of PG's has since
then been demonstrated in a variety of renal struc-
tures including glomeruli [29], collecting tubules
[30], interstitial cells [31], and blood vessels [321.
Arachidonic acid is released from membrane phos-
pholipids by an acylhydrolase, presumably phos-
pholipase A2, and then transformed by a cyclooxy-
genase to an endoperoxide intermediate that is the
common precursor of thromboxane A2 and of PG's
E2, F2, D2, and '2 [33, 34]. The predominant end-
product of PG endoperoxide metabolism differs
among the different cells and regions of the kidney
in relation to the distribution and activity of PG
endoperoxide metabolizing enzymes, for example,
PGI2 is a major derivative of arachidonic acid in the
cortex but not in the medulla of the kidney [35]. The
rate limiting step in overall PG biosynthesis is,
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however, the deacylation reaction that makes avail-
able nonesterified arachidonic acid [361.
In 1972, Terragno et al [51 and McGiff et a! [61
found that renal arterial infusion of bradykinin
increases the release of renal prostaglandins; this
finding has since then been confirmed by several
investigators. As there is no appreciable storage of
PG's in tissues, augmented release of PG's from an
organ denotes either enhanced biosynthesis or di-
minished degradation [33]. But, the release of renal
PG's elicited by bradykinin is caused by stimulation
of synthesis rather than by inhibition of PG degra-
dation. Several observations suggest that kinins
augment renal PG synthesis by stimulating phos-
pholipid deacylation and, consequently, making
available free arachidonic for conversion to cyclic
endoperoxides. (a) The release of PG's induced by
bradykinin from the isolated perfused lapine kidney
[36], and from lapine renomedullary interstitial cells
grown in culture [31], is associated with release of
arachidonic acid. (b) Renal arterial infusion of
bradykinin causes augmentation of renal phospholi-
pase activity in the rat [37]. And, (c) the phospholi-
pase A inhibitor, mepacrine, inhibits the release of
both arachidonic acid and PGE2 elicited by bradyki-
nm from rabbit renomedullary interstitial cells [31].
The deacylation reaction induced by bradykinin is
highly selective in that it brings about release of
arachidonic acid only [38]. This suggests that the
kinin either activates a specific lipase that distin-
guishes different fatty acids in the 2-position of
glycerophospholipids or, alternatively, that the Ii-
pase activated by the kinin is compartmentalized
with phospholipids containing arachidonic acid.
The range of products of arachidonic acid metab-
olism released by kinins from the kidney has not yet
been fully established. McGiff et al [61 found that
renal arterial infusion of bradykinin in the dog
stimulates release into renal venous blood of a
material that has the chemical, chromatographic,
and biological properties of PGE2. Others con-
firmed this finding and also reported elevation of
urine PGE2 during infusion of the peptide [36, 39—
431. Recently, it was found that bradykinin also
stimulates release of PGF2c. [41—43] and of PGI2 [44]
from the canine kidney. Interestingly, bradykinin,
previously believed to release only PGE2 from the
isolated perfused rabbit kidney, was shown to re-
lease also thromboxane A2 from the hydronephrotic
lapine kidney [451. Hence, considering that the
predominant end-product of PG endoperoxide me-
tabolism differs among different renal structures,
kinin peptides may promote synthesis of dissimilar
PG's in various cell types, and in the same cell type
during varying experimental conditions.
Relationship between the renal kallikrein-kinin and
prostaglandin systems
Evidence that the renal kallikrein-kinin system
influences production of renal PG's was first pro-
vided by studies on the effect of kininogen, the
inactive substrate of kallikrein, on PG release from
the rabbit kidney perfused ex vivo with Krebs
solution [40] (Fig. 2). Kininogen, like bradykinin,
was found to increase the venous and urinary efflux
of PG's, primarily of PGE2-like material. Aprotinin,
a kallikrein inhibitor, reduced the release of PG
induced by kininogen but not that by bradykinin.
This implies that augmentation of renal PG produc-
tion in response to kininogen requires conversion of
kininogen to a kinin. A corollary of this conclusion
is that kinins generated within the kidney cause
stimulation of renal PG production.
Additional evidence linking the renal kallikrein-
kinin and PG systems comes from studies on the
effect of kallikrein inhibition on urinary PG excre-
tion [46]. As PG's in urine arise within the kidney,
their rate of excretion is considered an index of
renal PG production. In the rat, daily administration
of the kallikrein inhibitor aprotinin (100,000 U/day)
reduced the urinary excretion of PGE2 by 63% and
67% after 1 and 3 days of treatment, and also
decreased kallikrein activity in both urine and renal
tissue (Fig. 3). Similarly, aprotinin reduced urine
PGE2 excretion in rats that had been pretreated
with DOCA to increase both renal kallikrein and
basal renal PGE2 production; the decrease in PGE2
excretion caused by the enzyme inhibitor was cor-
related with reduction of kallikrein activity in both
urine and the kidney. Aprotinin also reduced the
urinary excretion rate of PGE2 in the rat during
acute saline loading, which increases the basal
excretion of PGE2, and in the nonvolume—expanded
animal [47]. Inasmuch as the effect of aprotinin in
lowering urine PGE2 excretion is most likely related
to reduction of intrarenal kinin formation, these
observations suggest that a product of renal kalli-
krein activity promotes production of PGE2 by the
kidney.
Consonant with this conclusion are the results of
a recent study on the effect of inhibition of peptidyl
dipeptidase (kininase II or angiotensin I converting
enzyme) on urine PGE2 excretion in the rat pre-
treated with DOCA [481. Inhibition of this enzyme
reduces intrarenal kinin degradation, resulting in
increased kinin levels within the kidney reflected by
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urine PGE2 excretion correlated positively with
increased output of urinary kallikrein [50, 51]. Simi-
larly, the excretion into urine of both PGE2 and
kallikrein increases during the early phase following
administration of ioop diuretics [52, 531; in one
study the rise in urine PGE2 caused by furosemide
(1 mg/kg, i.v.) in normal subjects was correlated
positively with increments in urinary excretion of
kinins and kallikrein [52]. DOCA (5 mg/day), or
aldosterone (0.25 mg/day), after a few days of
treatment, increases the urinary output of both
kallikrein and PGE-like material in the rat [46].
Also, in the dog, the administration of DOCA
resulted in elevation of kallikrein [541 and PGE2 [551
in urine. Another mineralocorticoid, fludrocorti-
sone (0.2 mg/day), which causes elevation of uri-
nary kallikrein, also was reported to increase urine
PGE2 and PGF2 excretion in man [561. A positive
relationship between urine PGE2 and kallikrein is
not always apparent, however, despite evidence
suggesting that a product of renal kallikrein pro-
motes renal PG production. Normal subjects re-
ceiving DOCA (20 mg/day) for 10 days exhibit
elevated urinary excretion of kallikrein but not of
PGE2 1157]. Similarly, deprivation of dietary sodium
for 12 days in the rat results in augmented kallikrein
excretion, whereas the urinary output of both PGE-
and PGF-like material falls [581. It is possible that in
such instances the renal kallikrein-kinin system
influences renal production of arachidonic acid
metabolites other than PGE2.
The sites and regions where the renal kallikrein-
kinin and PG systems interact are not established
nor is the route followed by lysyl-bradykinin to sites
of PG synthesis (Fig. 1). Because renal kallikrein is
a cortical enzyme, it is conceivable that its peptide
product promotes PG synthesis in renal cortical
structures. Also, it is possible that lysyibradykinin
produced in the distal nephron travels via the tubule
to the renal medulla where the peptide stimulates
production of PG's in cellular elements associated
with the collecting tubules, the medullary intersti-
tium, and blood vessels. An additional possibility,
suggested by the finding of small amounts of kalli-
krein in the medulla and papilla of the kidney, is
that tubular fluid kallikrein crosses the collecting
duct epithelium and enters the medullary intersti-
tium to generate a kinin close to sites of PG
synthesis in the renal medulla. An alternate route of
transport of kallikrein and kinins via the blood
stream to sites of PG synthesis in the renal medulla
cannot be excluded.
The kinin-prostaglandin relationship in relation to renal
function
Renal arterial infusion of bradykinin stimulates
renal synthesis of PGE2 and PGI2, and this is
associated with effects on renal hemodynamic and
excretory functions similar to those of arachidonic
acid, PGE2, and PGI2. Evidence that one or more
products of arachidonic acid metabolism by the
kidney contribute to the effects of kinins on renal
function comes from work comparing such effects
before and during inhibition of PG synthesis. Modi-
fication of the effects of kinins on renal function
during PG synthesis blockade suggests involvement
of PG's in those effects.
Relation to prostaglandin synthesis of kinin ef-
fects on renal hemodynamics. Renal arterial infu-
sion of bradykinin produces vasodilatation and in-
creases the blood flow to the kidney [24, 39, 42, 431.
In the canine kidney perfused ex vivo with blood,
inhibition of PG synthesis was reported to reduce
the vasodilatory action of the peptide [59]. But,
several other studies indicate that PG synthesis
inhibition does not reduce the elevation in blood
flow to the kidney caused by bradykinin in the dog
[39, 42, 431. It appears, then, that PG's produced by
the kidney during infusion of bradykinin in vivo do
not contribute to the renal circulatory actions of
kinins. This is puzzling because two of the arachi-
donic acid metabolites released from the kidney by
bradykinin, for example, PGE2 and PGI2, have a
demonstrated capacity to produce renal vasodilata-
tion [60, 611.
Recent studies suggest that stimulation of renal
PG synthesis by kinins results in reduction of renal
vascular reactivity to sympathetic stimuli and All.
Malik and Nasjletti [62] found that bradykinin (1 to
100 ng/ml) reduces the vasoconstrictor responses
elicited by either norepinephrine or renal nerve
stimulation and greatly enhances the renal output of
a PGE-like material in the rabbit kidney perfused ex
vivo with Tyrode's solution. They also found that
indomethacin (1 ig/ml), an inhibitor of cyclooxy-
genase, causes reduction of the inhibitory action of
bradykinin on adrenergically induced renal vaso-
constriction. These findings have been confirmed in
the pentobarbital-anesthetized dog [63], viz., brady-
kinin infused intrarenally (10 ngkg'min1) inhibits
the lowering of renal blood flow caused by electrical
stimulation of the renal nerves or by norepineph-
rine, an effect that is not apparent in the dog
pretreated with the PG synthesis inhibitor sodium
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meclofenamate. These observations suggest that
the kinin acts at postjunctional sites to reduce
adrenergically-induced renal vasoconstriction
through a mechanism involving PG's. The effect of
bradykinin in reducing reactivity of the renal vascu-
lature to vasoconstrictor stimuli is not restricted to
norepinephrine only. Renal arterial infusion of bra-
dykinin (10 ngkg'min') also reduces the vasocon-
strictor effect of All in the canine kidney [64]. That
the inhibitory action of the kinin on All-induced
renal vasoconstriction is dependent on the synthe-
sis of PG is inferred from the observation that such
an action is not apparent in the dog pretreated with
an inhibitor of cyclooxygenase [64].
Collectively, these observations suggest that bra-
dykinin reduces the reactivity of the renal vascula-
ture to pressor hormones by a mechanism related to
PG synthesis. Consonant with this interpretation
are observations that the major PG's released from
the kidney by bradykinin, PGE2, and PGI2, also
attenuate All and norepinephrine-induced vasocon-
striction in the kidney [64, 651. From this it may be
inferred that one or more PG's produced by the
kidney during infusion of bradykinin mediate the
action of the peptide in reducing the reactivity of
the renal vasculature to All and adrenergic stimula-
tion.
Relation to prostaglandin synthesis of kinin ef-
fects on renal excretory functions. Renal arterial
infusion of kinins increases, like PGE, and PGI2,
the volume of urine and the excretion of sodium [24,
391. Inhibition of PG synthesis by sodium meclofen-
amate in the dog during water diuresis was found to
suppress both the bradykinin-induced output of
PGE2 and the associated natriuresis, suggesting
contribution of a PG or PG's to the effect of the
kinin in increasing urinary sodium [39]. Both brad y-
kinin and PGE2 increase urinary sodium excretion
by inhibiting sodium reabsorption by the distal
nephron. Injection of either PGE2 or bradykinin
into surface convolutions of later proximal tubules
in the rat inhibits the efflux of sodium 22 in distal
nephron segments [66, 67], which is consistent with
reduction of tubular reabsorption. PGE2 also inhib-
its sodium transport in isolated perfused segments
of lapine cortical and medullary collecting tubules
[681. It is possible, then, that PGE2 mediates the
kinin-induced natriuresis by reducing sodium reab-
sorption in the distal nephron.
The effect of bradykinin infused intrarenally in
increasing urine volume in the dog during water
diuresis appears unrelated to PG synthesis, that is,
it is not affected by PG synthesis blockade [39].
But, the diuretic action of bradykinin in the isolated
blood-perfused canine kidney was significantly re-
duced following inhibition of cyclooxygenase by
indomethacin [59]. PGE2 antagonizes the tubular
actions of vasopressin. As bradykinin augments
renal synthesis of PGE2, failure to detect the contri-
bution of the PG to the diuretic effect of the peptide
may relate to the particular experimental condi-
tions. For example, in the dog during water diure-
sis, the effect on urine volume of PGE2 synthesis
stimulation by a kinin is likely to be less apparent
because plasma vasopressin levels are low.
Physiological sign jfi cance of the relationship between
the renal kallikrein-kinin and arachidonate-
prostaglandin systems
The physiologic significance of the relationship
between the renal kallikrein-kinin and PG systems
is uncertain. Inasmuch as kinins stimulate renal
synthesis of arachidonic acid metabolites that in-
crease urinary sodium excretion and reduce the
reactivity of the renal vasculature to pressor hor-
mones, it is reasonable to propose that the relation-
ship between the renal kallikrein-kinin and PG
systems is a feature of mechanisms influencing
renal hemodynamic and excretory functions.
That the renal kallikrein-kinin system influences
the function of the kidney is inferred from reports
that the administration of inhibitors of kininase II,
or of an inhibitor of kallikrein, causes distinct
alterations of renal function. The rise in intrarenal
kinin levels following inhibition by teprotide of
kinin degradation is associated with renal vasodila-
tation, diuresis, and natriuresis [241. In contrast,
inhibition of kallikrein by aprotinin decreases renal
plasma flow, glomerular filtration rate, urine vol-
ume, and urinary excretion of sodium and potassi-
um in the saline-expanded rat, without affecting
blood pressure [47]. In another study, administra-
tion of aprotinin for 4 days to normal rats, or to rats
pretreated with DOCA, resulted in reduced sodium
excretion during the first 24 to 48 hours of treatment
but not thereafter [46]. Furthermore, bradykinin
antibodies, which are capable of blocking the bio-
logical actions of the peptide, were reported to
reduce the natriuretic response to saline loading in
the rat [69]. Collectively, the foregoing observa-
tions suggest that the renal kallikrein-kinin system
influences renal hemodynamic and excretory func-
tions by promoting vasodilatation and natriuresis.
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Positive evidence that PG's participate in such
mechanisms is lacking as yet. An increasing body of
evidence suggests, however, that renal PG's are
involved in the regulation of renal function. De-
pending on the experimental conditions, the activity
of vasoconstrictor systems, and the state of sodium
balance, PG's produced intrarenally influence renal
blood flow, its intrarenal distribution, the excretion
of water and electrolytes, and renal vascular reac-
tivity. This is inferred primarily from observations
that blockade of renal PG synthesis is associated
with: (a) lowering of renal blood flow during condi-
tions that cause elevation of All levels or of renal
sympathetic activity [70, 71]; (b) augmentation of
renal vascular reactivity to All and adrenergic
stimuli 72]; (c) increased sensitivity to vasopressin
[731; and (d) reduction of urinary sodium excretion
[731. These findings are taken as evidence that PG's
produced by the kidney influence its function by
promoting vasodilatation, opposing the vasocon-
strictor actions of All and norepinephrine, antago-
nizing the actions of vasopressin on water reabsorp-
tion, and interferring with sodium reabsorption.
It is apparent from these considerations that
relationships between the renal kallikrein-kinin and
PG systems may be an integral part of mechanisms
regulating the function of the kidney. Implicit in this
is the assumption that the product of renal kallikrein
activity stimulates renal production of arachidonic
acid metabolites that affect renal hemodynamic and
excretory functions. But, the available information
does not permit definite conclusions about the
physiologic significance of the relationship between
the renal kallikrein-kinin and PG systems.
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